Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma in Situ 1

Interventions

Sunitinib 2Paclitaxel 2valrubicin 1temsirolimus 1sipuleucel-T 1luprolide acetate gel depot 1ferumoxtran-10 1abiraterone 1abemaciclib 1Suspensions 1Surveys and Questionnaires 1Standard of Care 1Radiotherapy 1Prednisone 1Prednisolone 1Powders 1Pemetrexed 1Neoadjuvant Therapy 1National Cancer Institute (U.S.) 1Mitomycin 1Magnetic Resonance Spectroscopy 1Leuprolide 1Fatty Acids, Omega-3 1Educational Status 1Docetaxel 1Bevacizumab 1Atorvastatin 1Administration, Intravesical 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urogenital Neoplasms × valrubicin × Clear all
NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡